ARA-290 16mg

What is ARA-290?

ARA-290 is a synthetic research peptide modeled after a small protective region of the natural hormone erythropoietin. In lab settings, ARA-290 peptide 16mg is often explored in models related to nerve health, inflammation, and tissue protection. Researchers value it because it aims to keep the protective effects of erythropoietin while avoiding its blood-building activity. (Frontiers)

Each vial of ARA-290 peptide contains 16mg of lyophilized (freeze-dried) powder. Labs reconstitute this powder with a suitable sterile solution before use, following their own standard operating procedures (SOPs) and safety guidelines.

• Peptide type: Single synthetic erythropoietin-derived peptide, designed to be non-erythropoietic.
• Vial content: 16mg lyophilized powder for laboratory reconstitution.
• Primary research focus: Nerve and microvascular models, inflammation and tissue-protection models in preclinical research.

---

ARA-290 Peptide Overview & Key Properties

ARA-290 (also known as cibinetide or helix B surface peptide) is an 11-amino-acid peptide engineered from the tissue-protective domain of erythropoietin. It is designed to engage tissue-protection pathways without increasing red blood cell production, making it a targeted tool for advanced research peptides work. (Frontiers)

In the lab, ARA-290 peptide is supplied as a 16mg lyophilized powder. It is typically stored cool, dry, and away from light according to lab SOPs, and reconstituted right before use for in vitro or in vivo studies.

• Peptide class or family: Erythropoietin-derived, non-hematopoietic peptide that targets tissue-protection pathways rather than red-cell production. (PMC)
• Vial content and typical lab handling: 16mg lyophilized powder per vial, reconstituted under sterile conditions in controlled lab environments.
• Suggested storage concept in lab settings: Keep sealed vials cool, dry, and shielded from light; follow institutional stability and storage SOPs.
• Common research models: Cell studies, rodent models, and other preclinical systems focused on neuropathy, microvascular function, ischemia (limited blood flow) and stress-related tissue injury. (PLOS)

---

ARA-290 Mechanism of Action

ARA-290 is designed to work through a receptor complex called the “innate repair receptor” (IRR). This receptor is formed by the erythropoietin receptor paired with the β-common receptor (CD131). When ARA-290 binds to this complex in stressed tissues, it can trigger cell-protective signaling and reduce pro-inflammatory activity in many experimental models. (PMC)

Preclinical and early clinical research suggests that IRR activation by ARA-290 may help limit cell stress, support microcirculation (small blood vessel function), and modulate immune responses in various models of nerve and tissue injury. Studies have reported reduced inflammatory markers, better nerve fiber structure, and protection against damage in conditions such as autoimmune nerve injury, ischemic brain injury, and oxidative stress models. (PLOS)

---

ARA-290 Peptide Research

1. ARA-290 and Nerve Health Models

A key focus for ARA-290 peptide for research is small-fiber and peripheral nerve models. In animal models of autoimmune neuritis and neuropathy, ARA-290 has been shown to reduce inflammatory cell build-up around nerves and support healthier nerve function, suggesting a potential protective effect on nerve tissue. (PLOS)

Human clinical studies in people with sarcoidosis and symptoms of small fiber neuropathy have reported improvements in neuropathic symptom scores, measures of quality of life, and structural markers like corneal nerve fiber density after ARA-290 administration. These findings are exploratory and research-only; they do not represent approved medical use. (PMC)

2. ARA-290 and Inflammation / Immune Modulation

Several studies describe ARA-290 as a tissue-protective and immunomodulatory peptide. In experimental nerve injury and autoimmune models, ARA-290 has been observed to reduce pro-inflammatory cytokines (cell signaling proteins that drive inflammation) and shift immune cells toward a more balanced profile. (PLOS)

A broader review of erythropoietin-derived peptides, including ARA-290, notes reductions in systemic inflammation and improved outcomes across different cardiovascular and metabolic models, such as diet-induced insulin resistance and experimental myocardial injury. These are preclinical observations and should be interpreted as early-stage research only. (PMC)

3. ARA-290 and Ischemia / Tissue Protection Models

In ischemia models, where tissues are temporarily deprived of blood and oxygen, ARA-290 has been explored for its potential to protect cells and reduce damage. Mouse studies of cerebral ischemic stroke have found that ARA-290, acting through the β-common receptor, can lessen tissue injury and support better structural outcomes in the brain. (PubMed)

Other experimental work suggests that ARA-290 may reduce oxidative stress and cell death in models exposed to toxic chemotherapeutic agents, and may protect isolated human islets in inflammatory environments. These results are limited to controlled lab conditions and do not imply any approved clinical application. (PubMed)

4. ARA-290 and Stress / Mood-Related Models

Beyond nerve and tissue studies, ARA-290 peptide has also been evaluated in preclinical models of chronic stress. In mouse models of chronic unpredictable mild stress and social defeat stress, ARA-290 administration was associated with reduced “depression-like” behaviors, along with shifts in immune cell activity and microglial activation in the brain. (Frontiers)

These findings support ongoing interest in ARA-290 as a research tool for neuroimmune interactions—how the immune system and brain talk to each other—under chronic stress. However, such results in animals do not equal proven mood effects or any approved indication in humans.

---

ARA-290 Peptide Dosing Concepts for Lab Research

This section is educational, not prescriptive.

In laboratory research, dosing for ARA-290 peptide 16mg is based on each lab’s study design, model type, and institutional review standards. Researchers typically explore a range of doses in cell or animal models, looking at how different exposure levels change biomarkers, tissue structure, or behavior over time. Published studies often compare multiple dose levels and time points to map both short-term and longer-term responses. (PLOS)

• Focus: Standardizing how much peptide each model receives so that results are consistent and easier to compare across experiments.
• Study design: Using time-course sampling (for example, early vs later time points) and control groups to understand how ARA-290 behaves versus placebo or other comparators.
• Use the peptide dosage calculator to plan vial reconstitution and aliquots.

---

ARA-290 Peptide Specifications Table

Parameter	Details
Peptide name	ARA-290 peptide
Vial content	16mg (lyophilized powder)
Peptide type	Single peptide
Typical use case	Preclinical nerve, inflammation, and tissue-protection models
Storage guidance	Cool, dry, dark; follow lab SOPs
Intended use	Laboratory research only, not for human use

---

ARA-290 Peptide FAQs

What is ARA-290 peptide used for in research?

In research settings, ARA-290 peptide is often used in models that look at nerve health, inflammation, and tissue protection. Scientists may study how it affects small nerve fibers, immune signaling, or tissue recovery after stress or reduced blood flow. All of this work is experimental and meant to better understand basic biology, not to provide medical treatment. (PLOS)

How is ARA-290 peptide typically stored in a lab?

Labs usually store ARA-290 peptide 16mg as a sealed, lyophilized powder in a cool, dry, and dark environment. After reconstitution with a suitable sterile solution, many labs keep aliquots refrigerated or frozen according to their SOPs and stability data. Always, local lab guidelines and safety policies take priority.

Is ARA-290 peptide similar to any other well-known peptides?

ARA-290 is related to erythropoietin in that it is built from a small segment of the erythropoietin molecule, but it is engineered not to stimulate red blood cell production. Instead, it is designed to focus on tissue-protective and anti-inflammatory signaling through the innate repair receptor. This makes it different from classic erythropoietin use in both design and research intent. (Frontiers)

Does ARA-290 have human clinical data?

Yes, ARA-290 (cibinetide) has been studied in several early-phase clinical trials, including sarcoidosis-related small fiber neuropathy and eye-related vascular conditions. These trials reported improvements in certain symptom scores and structural measures, but they are exploratory and do not mean ARA-290 is approved for any medical use. It remains a research compound. (PMC)

How does ARA-290 differ from standard erythropoietin in research?

Standard erythropoietin can increase red blood cell counts, which may limit its use in some models. ARA-290 was designed to avoid this blood-building effect while still engaging tissue-protective pathways via the innate repair receptor. This distinction lets researchers focus on its cell-protective and immune-modulating actions without confounding changes in hematocrit in preclinical studies. (Frontiers)

Where to buy ARA-290 online?

You can buy ARA-290 peptide 16mg online in the United States at Protide Health. Every compound is backed by science, clearly labeled, and third-party tested as part of a research-only product catalog. When you buy ARA-290 peptide, always use it within appropriate laboratory and regulatory guidelines.

Is ARA-290 peptide for self-use or supplementation?

No. ARA-290 peptide is not a supplement and is not intended for self-administration. It is supplied strictly for controlled laboratory and preclinical research, and must only be handled by trained personnel following proper safety and regulatory procedures.

---

Conclusion: Summary of ARA-290 Peptide for Research

ARA-290 peptide 16mg is a synthetic, erythropoietin-derived research peptide designed to activate tissue-protective signaling pathways without driving red blood cell production. Supplied as a lyophilized powder, it fits well into preclinical workflows that explore nerve health, inflammation, and tissue-protection biology. (Frontiers)

From small fiber neuropathy and nerve injury models to ischemia and chronic stress studies, ARA-290 peptide has become a valuable tool for labs interested in neuroimmune and microvascular pathways. All current work remains research-focused, and ARA-290 is intended only for controlled laboratory use—not for human consumption or therapeutic use.

---

Citations

• Brines M et al., 2015. ARA 290, a non-erythropoietic peptide engineered from erythropoietin’s tissue-protective domain. Molecular Medicine / PMC. (PMC)
• Winicki NM et al., 2023. Small erythropoietin-derived non-hematopoietic peptide and cardiovascular/metabolic implications. Frontiers in Cardiovascular Medicine. (Frontiers)
• Liu Y et al., 2014. Erythropoietin-derived peptide ARA 290 in experimental autoimmune neuritis. PLOS ONE. (PLOS)
• Heij L et al., 2012. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy. Molecular Medicine. (PMC)
• van Velzen M et al., 2014. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opinion on Investigational Drugs / PubMed. (PubMed)
• Culver DA et al., 2017. Cibinetide improves corneal nerve fiber abundance in sarcoidosis. Investigative Ophthalmology & Visual Science. (IOVS)
• Wang RL et al., 2024. ARA 290 mediates brain tissue protection through the β-common receptor in cerebral ischemic stroke models. CNS Neuroscience & Therapeutics / PubMed. (PubMed)
• Shokrzadeh M et al., 2020. ARA 290 attenuates oxidative stress and cell death in doxorubicin models. Fundamental & Clinical Pharmacology / PubMed. (PubMed)
• Xu G et al., 2022. Nonerythropoietic erythropoietin mimetic peptide ARA 290 in chronic stress-related behavior models. Frontiers in Pharmacology. (Frontiers)
• Nairz M et al., 2017. Cibinetide dampens innate immune cell functions in inflammatory settings. Scientific Reports. (Nature)

---

Legal Disclaimer for ARA-290 Peptide

The information provided in this description is for research purposes only. The ARA-290 peptide is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for human consumption or therapeutic use. It is intended solely for investigational use in controlled laboratory settings by qualified researchers. Protide Health does not endorse or promote the use of ARA-290 peptide in humans or animals outside of approved research protocols. Researchers must comply with all applicable local, state, and federal regulations, including obtaining necessary approvals for experimental use. Consult with regulatory authorities before initiating any research involving ARA-290 peptide.

Products sold by Protide Health are for laboratory research purposes only and are not intended for human consumption, medical use, or veterinary use.